摘要:
Substituted thiophenesulfonylureas and -thioureas I ##STR1## wherein R(1) is selected from the group consisting of hydrogen, halogen, alkyl having 1 or 2 carbon atoms, alkoxy having 1 or 2 carbon atoms, mercaptoalkyl having 1 or 2 carbon atoms, fluoroalkoxy having 1 or 2 carbon atoms, and fluoroalkyl having 1 or 2 carbon atoms; R(2) is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms such as methyl, alkoxy having 1 or 2 carbon atoms, and trifluoromethyl; X is selected from the group consisting of oxygen (compounds Ia) or sulfur (compounds Ib); Y and Z are identical or different and are selected from the group consisting of hydrogen, F, Cl, Br, I, alkyl having 1 or 2 carbon atoms and alkoxy having 1 or 2 carbon atoms.
摘要:
Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and pharmaceutical preparations containing them.Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.
摘要:
Substituted chromanylsulfonyl(thio)ureas, processes for their preparation, their use in pharmaceutical preparations, and pharmaceutical preparations comprising them Chromanylsulfonyl(thio)ureas of the formula I ##STR1## are useful pharmaceuticals for the treatment of cardiac arrhythmias and for the prevention of sudden heart death due to arrhythmia. They can be used as antiarrhythmics and are suitable for the prevention of sudden heart death, for the treatment of cardiac insufficiency and also heart failure as a result of the effects of shock.
摘要:
The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.
摘要:
The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.
摘要:
Novel synthetic isohirudins with improved stability The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.
摘要:
Thrombin inhibitors from the hirudin family which differ from the previously known hirudins by mutation in the protein chain, and a process for their preparation are described. The novel hirudins are distinguished by a high specific activity, high stability and good pharmacokinetics.
摘要:
A hirudin derivative which has the N-terminal amino acid sequence Leu-Thr-Tyr-Thr-Asp shows high biological activity. Moreover, this hirudin derivative can be obtained very efficiently by genetic engineering preparation in yeasts.
摘要:
Benzo-fused heterocyclic compounds having a 5-membered ring, processes for their preperation, their use as medicaments, their use as diagnostic agents and medicaments containing them. Benzo-fused heterocyclic compounds having a 5-membered ring, of the formula I ##STR1## where X is N or CR(6); Y is oxygen, S or NR(7); A and B together are a bond or are both hydrogen, if, at the same time, X is CR(6) and Y is NR(7), one of the substituents R(1) to R(6) is a --CO--N.dbd.C(NH.sub.2).sub.2 group; the other respective substituents R(1) to R(6) are H, Hal or alkyl; up to two of the other substituents R(1) to R(6) are CN, NO.sub.2, N.sub.3, (C.sub.1 -C.sub.4)-alkoxy, CF.sub.3 ; up to one of the other substituents is R(8)--C.sub.n H.sub.2n --Z-- or phenyl; R(7) is H, alk(en)yl or R(8)--C.sub.n H.sub.2n --, and pharmaceutically tolerated salts there of, are described. A process f or the preparation of the compounds I which comprises reacting a compound of the formula II ##STR2## in which one of the substituents R(1)' to R(5)' is a --CO--L group and L is a leaving group which can easily be replaced nucleophilically, with guanidine, and, if appropriate, converting the product into the pharmacologically tolerated salt, furthermore is also described.
摘要翻译:具有5元环的苯并稠合杂环化合物,其制备方法,用作药物,用作诊断剂和含有它们的药物。 具有5元环的苯并稠合杂环化合物,其中X为N或CR(6);其中X为N或CR(6); Y是氧,S或NR(7); 如果同时X是CR(6),Y是NR(7),则取代基R(1)〜R(6)中的一个是-CO -N = C(NH 2)2基团; 其它各取代基R(1)〜R(6)为H,Hal或烷基; 最多两个其它取代基R(1)-R(6)是CN,NO 2,N 3,(C 1 -C 4) - 烷氧基,CF 3; 最多一个其它取代基是R(8)-C n H 2n-Z-或苯基; R(7)为H,烷(烯)基或R(8)-C n H 2n - 及其药学上耐受的盐。 方法f或化合物I的制备,其包括使式II(II)化合物与其中一个取代基R(1)'与R(5)'为-CO-L基团的化合物反应, L是一种离去基团,其可以容易地被核苷酸替代,并且如果合适,将产物转化成药理学上耐受的盐,此外还被描述。